U.S. Hemodialysis Devices Market

Market Outlook

By 2035, the U.S. Hemodialysis Devices Market is expected to reach approximately USD 12.50 billion, expanding at a CAGR of 8.32% during the forecast period 2026–2035. The market is estimated at USD 5.62 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The historical market expanded from approximately USD 4.63 billion in 2021 to USD 5.38 billion in 2024, supported by the continued treatment requirements of patients with end-stage kidney disease, normalization of dialysis-center activity following pandemic-era disruption, rising use of high-flux dialyzers, replacement of aging dialysis machines, and increasing investment in home-capable hemodialysis platforms. The market reached an estimated USD 5.62 billion in 2025, reflecting a revenue base dominated by recurring dialyzers, bloodline sets, concentrates, vascular-access products, and other treatment consumables.

Hemodialysis remains the principal dialysis modality in the United States and consequently supports one of the most predictable recurring-use device markets in healthcare. The latest national renal-disease data identify more than 933,000 adults living with treated end-stage kidney disease, including approximately 675,000 patients receiving dialysis and nearly 589,000 receiving hemodialysis. This installed patient base generates continuous utilization of machines, dialyzers, extracorporeal blood circuits, fistula needles, catheters, dialysate concentrates, water-treatment systems, monitoring equipment, and associated disposables.

The addressable demand pool is substantially larger than the current dialysis population. Approximately 35.5 million U.S. adults are estimated to have chronic kidney disease, and diabetes, hypertension, cardiovascular disease, obesity, aging, and delayed CKD diagnosis continue to feed progression into advanced renal disease. For device manufacturers, however, market growth will not be determined by epidemiology alone. Revenue expansion increasingly depends on technology mix, treatment setting, dialysis intensity, consumables attachment, clinical staffing economics, reimbursement design, and the ability of new platforms to change how and where dialysis is delivered.

A major transition is beginning within U.S. hemodialysis technology. Conventional three-times-weekly in-center treatment will remain the dominant volume model through 2035, but the device value pool is moving toward simplified home hemodialysis, digitally connected treatment systems, high-volume hemodiafiltration, advanced dialyzer membranes, automated setup and priming, remote treatment surveillance, and integrated water-management architectures.

The economics of the U.S. dialysis industry also create unusually strong incentives for workflow improvement. Medicare’s ESRD Prospective Payment System bundles most outpatient dialysis services into a per-treatment reimbursement structure. The 2025 base payment rate was approximately USD 273.82 per treatment, while the 2026 base rate increased to approximately USD 281.71. Medicare projected payments to thousands of dialysis facilities annually under this framework. As a result, dialysis providers have a direct financial reason to evaluate machines and consumables based on total treatment economics rather than acquisition cost alone.

The strongest device propositions during 2026–2035 will therefore be technologies that lower nursing burden, reduce setup and teardown time, decrease water and concentrate consumption, improve treatment reliability, enable higher patient throughput, support home transition, simplify inventory, generate actionable treatment data, or permit differentiated therapies without materially increasing operating complexity.

Introduction

According to the U.S. Hemodialysis Devices Market Report, hemodialysis is one of the most operationally intensive recurring medical procedures performed at scale in the United States. Unlike episodic device markets where revenue depends primarily on new diagnoses or surgical procedures, hemodialysis generates a repeated treatment cycle for patients whose kidneys can no longer adequately remove metabolic waste and excess fluid.

For a typical maintenance-hemodialysis patient, treatment may occur several times each week for years unless the patient receives a successful kidney transplant, changes modality, recovers kidney function in selected circumstances, or dies. This treatment frequency creates a durable commercial model in which capital machines produce a large downstream stream of disposable-device revenue.

The U.S. market evaluated in this report includes hemodialysis delivery machines, dialyzers, extracorporeal bloodline and tubing systems, dialysis-specific vascular-access devices, dialysate concentrates, water-treatment and purification systems, treatment cartridges, and related hemodialysis consumables. The market excludes dialysis-service revenue and excludes equipment used exclusively for peritoneal dialysis. This distinction is important because the economic value of dialysis services is several multiples larger than the underlying medical-device market.

The U.S. dialysis delivery infrastructure is highly developed but concentrated. In 2025, Medicare payment policy referenced approximately 7,700 ESRD facilities, while the two largest dialysis organizations alone operated more than 5,200 U.S. outpatient dialysis centers. This concentration materially affects device commercialization. A manufacturer that secures an enterprise agreement with a major dialysis organization can access treatment volumes that would require hundreds or thousands of individual hospital contracts in other medical-device categories.

At the same time, purchasing power is correspondingly concentrated. Large dialysis organizations possess sophisticated procurement departments, clinical standardization capabilities, large internal datasets, and considerable leverage over machine pricing, consumable contracting, service agreements, and supplier qualification. New entrants therefore require more than an FDA-cleared machine. They must demonstrate supply continuity, field-service capability, reliable consumables manufacturing, clinician usability, training infrastructure, interoperability, and compelling economics at fleet scale.

The market is also changing technologically. U.S. hemodialysis has historically lagged some international markets in widespread adoption of high-volume hemodiafiltration. Recent regulatory clearances and clinical implementation of HDF-capable platforms are beginning to alter that trajectory. In parallel, portable and simplified systems from newer manufacturers are challenging assumptions that hemodialysis must always depend on large machines, centralized water infrastructure, and highly specialized clinical workflows.

From 2026 to 2035, competitive advantage will increasingly shift from isolated hardware specifications toward integrated treatment ecosystems combining capital equipment, disposables, fluid management, software, remote monitoring, predictive maintenance, clinical workflow automation, and reimbursement-compatible care models.

Key Market Drivers: What’s Fueling the U.S. Hemodialysis Devices Market Boom?

The most fundamental growth driver is the large and persistent U.S. kidney-disease burden. More than one in seven adults has chronic kidney disease, while hundreds of thousands have progressed to kidney failure requiring dialysis or transplantation. Because CKD is frequently asymptomatic until advanced stages, the U.S. continues to generate a significant population requiring renal replacement therapy despite improvements in diabetes, hypertension, and cardiovascular management.

The hemodialysis population itself provides a powerful recurring-volume foundation. Nearly 589,000 adults were receiving hemodialysis in the latest national treatment cohort, considerably exceeding the number receiving peritoneal dialysis. Each active hemodialysis patient requires repeated access to dialyzers, tubing, vascular-access components, fluid-management products, and machine capacity. Consequently, modest growth in patient count can translate into substantial incremental disposable consumption.

A second driver is the recurring economics of dialysis consumables. Hemodialysis machines are important strategically, but disposable products generate the majority of market revenue. Dialyzers, blood tubing, fistula needles, catheter-related products, cartridges, concentrates, disinfectants, and other single-treatment supplies are consumed continuously. The report estimates that consumables and treatment-related disposable products account for approximately 84%–85% of U.S. hemodialysis-device revenue, making installed-machine placement an important mechanism for securing long-term consumable demand.

A third driver is the aging of the U.S. population. Kidney function naturally declines with age, while diabetes, hypertension, cardiovascular disease, and multimorbidity become more common among older adults. Approximately half of the current adult hemodialysis population is aged 65 years or older. Aging therefore affects not only dialysis incidence but also the complexity of treatment, vascular-access management, fluid-control requirements, hospitalization risk, and demand for systems designed for clinically fragile patients.

A fourth driver is persistent diabetes and hypertension. These conditions remain major causes of kidney failure in the United States. Their combined prevalence creates a large upstream pool of patients at risk of progressive renal impairment. States with high rates of diabetes, hypertension, obesity, cardiovascular disease, and socioeconomic barriers to preventive nephrology tend to generate particularly strong dialysis demand.

A fifth driver is the continuing movement toward home-based kidney care. Home hemodialysis remains much smaller than conventional in-center treatment, but policy, technology, and patient preference are increasingly aligned around greater treatment flexibility. CMS reimbursement policy includes training-related support for home and self-dialysis modalities, while Medicare expanded the ability to furnish dialysis for selected acute kidney injury beneficiaries in the home beginning in 2025.

Home hemodialysis changes device requirements substantially. A machine developed for a large dialysis center cannot simply be relocated into a patient’s home without redesigning usability, installation, water management, supply logistics, alarm handling, remote support, and training. This creates a distinct premium-growth category for manufacturers capable of reducing complexity sufficiently for patients and caregivers.

A sixth driver is clinical staffing pressure. Dialysis centers are labor-intensive, and nursing and technician availability is an important operating constraint. Systems that automate priming, rinse-back, disinfection, treatment documentation, conductivity monitoring, prescription loading, or workflow steps can create meaningful economic value even when their acquisition price is higher.

For a large provider, saving a few minutes per station per treatment can compound across millions of annual treatments. This explains why workflow automation is increasingly central to equipment-selection criteria.

A seventh driver is the introduction of high-volume hemodiafiltration into the U.S. commercial landscape. HDF combines diffusive and convective solute removal and has been used extensively outside the United States. FDA clearance of HDF-capable systems and initial U.S. deployments represent a significant technology-cycle event for the domestic dialysis market.

If high-volume HDF gains broad clinical adoption, it could stimulate replacement of existing machine fleets, create differentiated tubing and fluid-management requirements, influence dialyzer selection, and increase demand for ultrapure water infrastructure. The opportunity extends beyond one machine platform because competitive suppliers are likely to develop compatible equipment, consumables, monitoring technologies, and services.

An eighth driver is consolidation among dialysis providers and health systems. Large dialysis networks can standardize purchasing across hundreds or thousands of locations. Consolidation can initially create procurement pressure on device ASPs, but it can also accelerate adoption when a manufacturer demonstrates sufficiently strong clinical and economic value. Enterprise standardization allows approved systems to scale much faster than in fragmented hospital categories.

Finally, reimbursement remains a critical market driver. Medicare’s ESRD bundled payment system rewards providers that control treatment cost while maintaining quality. Technologies capable of reducing hospitalization, vascular-access complications, missed treatment, staff time, consumables waste, machine downtime, or home-program failure therefore have economic value extending beyond their direct device cost.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in U.S. hemodialysis is moving away from incremental changes in basic pumping hardware toward broader redesign of the treatment workflow. The core filtration concept is mature; competitive differentiation increasingly comes from how easily, safely, consistently, and economically therapy can be delivered.

One of the most strategically important changes is the arrival of high-volume hemodiafiltration-capable systems. HDF requires sophisticated fluid balancing, online preparation of substitution fluid, high-quality water, compatible bloodline systems, and rigorous monitoring. Commercial adoption can therefore generate demand across an entire technology stack rather than only the dialysis machine.

The FDA clearance of Fresenius Medical Care’s 5008X platform during 2025 helped establish a pathway for broader U.S. HDF adoption. Initial treatments undertaken in the U.S. marked an important shift because the domestic dialysis infrastructure had historically been centered overwhelmingly on conventional HD.

A second innovation theme is automation. New systems increasingly automate tasks that previously required manual intervention by nurses or technicians. Automated priming, self-testing, prescription transfer, disinfection routines, fluid preparation, alarm guidance, and treatment documentation reduce dependence on repetitive human steps.

Nikkiso’s DBB-06 PRO, cleared by the FDA in 2025, reflects this direction through automated treatment-preparation features intended to reduce staff workload. Similar workflow design principles are likely to become increasingly important as dialysis providers face labor shortages and rising compensation costs.

A third area is simplified and compact hemodialysis. Outset Medical’s Tablo, Quanta’s SC+ platform, and Diality’s Moda-flx illustrate an emerging design philosophy that attempts to reduce infrastructure and operational complexity. Rather than assuming that the dialysis machine must be optimized solely for highly specialized dialysis units, manufacturers are designing systems that can function across hospitals, chronic dialysis facilities, transitional-care settings, or homes.

Quanta’s SC+ received FDA clearance for home use in 2024, reinforcing the opportunity for differentiated home HD platforms. The strategic significance extends beyond the number of patients currently treated at home. Home clearance creates a technology benchmark around training time, patient usability, cartridge-based consumables, remote support, and treatment flexibility.

A fourth innovation area is connectivity. Modern dialysis machines increasingly function as endpoints within a clinical information system rather than isolated pieces of equipment. Automatic prescription transfer, treatment-record capture, remote monitoring, fleet management, service diagnostics, cybersecurity, and integration with electronic records can reduce documentation burden and improve operational oversight.

For large dialysis networks, device connectivity can also support predictive maintenance. Dialysis-machine downtime has direct economic consequences because each unavailable station may reduce treatment capacity. Remote diagnostics and service analytics can therefore influence procurement decisions even when they do not directly alter clinical outcomes.

A fifth area is membrane technology. High-flux dialyzers already represent a major component of U.S. treatment, but manufacturers continue to differentiate products through membrane permeability, biocompatibility, middle-molecule clearance, surface characteristics, sterilization methods, and treatment-specific performance.

Medium cut-off and expanded-hemodialysis concepts aim to improve clearance of larger uremic toxins without requiring the complete fluid architecture of HDF. These technologies could become attractive to providers seeking incremental clinical differentiation while preserving familiar HD workflows.

A sixth innovation theme is water efficiency. Traditional hemodialysis can consume substantial volumes of purified water. Water purification also adds equipment, maintenance, testing, disinfection, and infrastructure requirements. Technologies that reduce water consumption, simplify purification, or generate dialysate on demand can improve both facility economics and home deployment feasibility.

Device safety will remain equally important. Hemodialysis equipment is exposed to complex fluid pathways, sensors, tubing, water systems, software, cleaning agents, and repeated operation. Recent device corrections involving dialysis systems demonstrate why material compatibility, software validation, alarm performance, manufacturing controls, and post-market surveillance remain central to competitive credibility.

Manufacturers that innovate rapidly without building equally strong quality systems can lose procurement confidence. In dialysis, trust is particularly difficult to rebuild because providers depend on equipment for repeated life-sustaining treatments across large installed fleets.

Segmentation Insights

The U.S. Hemodialysis Devices Market is segmented on the basis of product category, treatment modality and technology, clinical application, end user, and geography.

By Product Category

Hemodialysis Machines

Hemodialysis machines form the technological foundation of treatment delivery and represent an estimated 15%–16% of device-market revenue in 2025. The category includes conventional in-center machines, compact systems, home-use machines, HDF-capable platforms, and multi-therapy systems used in hospitals.

Machine revenue is driven less by annual treatment frequency than by fleet installation and replacement cycles. Large dialysis organizations operate thousands of treatment centers containing multiple stations per facility, creating a substantial installed equipment base requiring maintenance and periodic modernization.

Competition increasingly centers on lifetime operating cost. Providers evaluate equipment reliability, service responsiveness, water requirements, treatment setup time, connectivity, disposable attachment, and staff productivity. The fastest-growing machine subsegments through 2035 are expected to be home-capable systems, compact platforms, and advanced HDF-capable equipment.

Dialyzers

Dialyzers represent the largest individual disposable category and one of the most strategically important revenue pools in hemodialysis. Each treatment requires an artificial-kidney membrane through which solute and fluid exchange occurs.

U.S. demand is increasingly concentrated in high-flux synthetic membranes. Competitive differentiation includes membrane surface area, ultrafiltration characteristics, middle-molecule clearance, biocompatibility, sterilization technology, and compatibility with specific treatment protocols.

Because dialyzers are used repeatedly across millions of annual U.S. treatments, relatively small changes in price or share can translate into significant supplier revenue. Manufacturers with both machines and dialyzers possess an important contracting advantage because they can structure integrated equipment-and-consumable arrangements.

Bloodline Systems, Tubing Sets and Treatment Cartridges

Extracorporeal blood circuits are another major recurring revenue category. Bloodline systems connect the patient’s vascular access to the dialysis machine and dialyzer while supporting pumping, pressure monitoring, air detection, medication administration, and return of blood.

The segment is evolving as machines become more platform-specific. Cartridge architectures and dedicated tubing sets can simplify setup and reduce connection errors, but they also increase consumable dependence on the machine manufacturer.

This model is commercially attractive because a successfully placed machine can generate a predictable multi-year disposable stream. Providers, however, will scrutinize total cartridge and tubing cost because these expenses compound across treatment volumes.

Vascular Access Devices

Vascular access products include arteriovenous fistula needles, dialysis catheters, catheter accessories, guidewires, access-maintenance products, and related components. Reliable vascular access is essential because inadequate blood flow can limit treatment effectiveness and access complications can result in hospitalization or loss of the dialysis access site.

AV fistulas remain clinically important, but tunneled dialysis catheters continue to represent substantial device demand, particularly among incident patients and individuals without mature permanent access.

The economic importance of access products exceeds their direct selling price because infections, thrombosis, stenosis, access failure, and catheter complications can materially increase treatment cost.

Dialysate, Concentrates, Water-Treatment Systems and Other Consumables

This category includes acid and bicarbonate concentrates, water-purification equipment, reverse-osmosis systems, filtration components, disinfection products, treatment fluids, sensors, and other recurring supplies.

The category is operationally critical because dialysis fluid comes into indirect contact with the patient’s blood across the dialyzer membrane. Water quality therefore requires strict monitoring and purification.

Growth will be shaped by home dialysis, on-demand dialysate production, HDF requirements, ultrapure-water standards, sustainability objectives, and provider interest in reducing facility water consumption.

By Treatment Modality and Technology

Conventional In-Center Hemodialysis

Conventional in-center hemodialysis represents the largest treatment-technology segment and will remain the dominant revenue source throughout the forecast period. Most U.S. HD patients receive scheduled treatment in outpatient dialysis facilities, generally multiple times each week.

The size of this installed infrastructure creates significant inertia. Providers possess standardized machines, trained staff, established supply chains, service contracts, water infrastructure, and operating protocols. Consequently, new technologies must demonstrate a measurable improvement before large networks replace functioning assets.

Nevertheless, conventional HD will continue generating substantial recurring growth because every treatment consumes multiple disposable components.

High-Flux Hemodialysis

High-flux dialysis is a major component of contemporary U.S. maintenance therapy. High-permeability membranes allow increased movement of selected solutes compared with older low-flux technologies.

This segment benefits from the continued shift toward improved clearance profiles and newer membrane designs. Growth will primarily occur through premium dialyzer mix rather than dramatic increases in treatment frequency.

High-Volume Hemodiafiltration

High-volume HDF is expected to be the fastest-growing technology segment through 2035, albeit from a small U.S. base.

Commercial expansion will require machines capable of accurate online fluid management, suitable bloodline systems, high-flux dialyzers, adequate vascular access, robust water quality, and staff training. These requirements make HDF strategically important because it can influence multiple device categories simultaneously.

Adoption is likely to begin among large dialysis networks, academic nephrology centers, and clinically progressive facilities before spreading more broadly.

Home Hemodialysis

Home HD represents a relatively small share of the current U.S. hemodialysis patient population but one of the most important strategic growth markets.

The commercial model differs fundamentally from in-center dialysis. Home systems need intuitive interfaces, simplified consumable loading, remote technical support, compact footprints, manageable water requirements, patient-friendly alarm systems, and logistics capable of delivering supplies directly to residences.

Growth will depend on patient eligibility, caregiver support, provider training programs, reimbursement, housing conditions, and the ability of manufacturers to reduce the complexity traditionally associated with home dialysis.

Acute and Extended Hemodialysis Therapies

Hospitals use HD platforms for acute kidney injury, hospitalized chronic dialysis patients, and selected prolonged or low-efficiency treatment protocols.

This segment requires flexible machines that can operate in dialysis departments, intensive-care environments, or bedside settings. Demand is influenced by hospitalization patterns, ICU capacity, acute kidney injury incidence, and hospitals’ preference for platforms capable of supporting multiple renal-treatment protocols.

By Clinical Application

Chronic End-Stage Kidney Disease

Chronic ESKD represents the overwhelming majority of device demand. Patients typically require continuing dialysis treatment unless kidney transplantation becomes available or another modality is selected.

The large prevalent HD population provides manufacturers with a relatively predictable annual treatment base. Product success therefore depends strongly on securing contracts with established dialysis networks rather than only acquiring individual patients.

The chronic-maintenance segment is expected to remain the largest application through 2035 even as home HD and HDF change the technology mix within it.

Acute Kidney Injury

Acute kidney injury represents a smaller but strategically important application. Severe AKI may require temporary dialysis in hospitals or, increasingly, selected post-acute and home settings.

CMS’s 2025 expansion permitting payment for home dialysis services for qualifying Medicare beneficiaries with AKI creates additional flexibility in the care pathway. This may stimulate demand for systems capable of transitioning selected patients between hospital, outpatient, and home settings.

Cardiorenal and Fluid-Overload Management

Patients with severe cardiovascular disease, heart failure, fluid overload, or combined cardiorenal dysfunction may require ultrafiltration or dialysis-based fluid management.

These cases often involve medically complex patients whose tolerance of conventional rapid fluid removal may be limited. Equipment capable of precise ultrafiltration control and flexible treatment duration is particularly relevant.

Complex and High-Acuity Renal Failure

High-acuity patients may require prolonged intermittent renal replacement therapy, sustained low-efficiency dialysis, or other modified HD approaches.

Demand is concentrated within tertiary hospitals and large medical centers. Device manufacturers compete on reliability, treatment flexibility, alarm management, mobility, compatibility with hospital workflows, and ability to function without extensive permanent dialysis infrastructure.

Pediatric Hemodialysis

Pediatric HD represents a small portion of total device revenue but requires specialized clinical management because of lower blood volumes, smaller vascular access, fluid sensitivity, and dosing requirements.

Large children’s hospitals and academic centers constitute the principal demand base. Although commercially limited, pediatric capability can strengthen a manufacturer’s clinical positioning within comprehensive renal-care institutions.

By End User

Outpatient Dialysis Centers

Outpatient dialysis centers dominate U.S. hemodialysis-device consumption. The United States contains approximately 7,600–7,700 Medicare-participating ESRD facilities, with the largest dialysis chains operating thousands of sites.

These organizations purchase machines and consumables at substantial scale. Procurement therefore emphasizes contract economics, standardization, reliable supply, service responsiveness, machine uptime, staff training, and compatibility with centralized clinical protocols.

Large networks also possess the scale to test technologies internally before nationwide rollout. For manufacturers, winning a controlled pilot can therefore be considerably more valuable than generating isolated equipment placements.

Hospitals and Health Systems

Hospitals represent an important market for acute dialysis, hospitalized chronic ESKD patients, intensive-care renal support, and inpatient nephrology services.

Hospital procurement differs from outpatient dialysis-chain purchasing. Buyers may prioritize multipurpose flexibility, mobility, integration with hospital IT systems, infection-control workflows, emergency support, and compatibility with ICU treatment patterns.

Academic hospitals can also act as early adopters of HDF, advanced membranes, and novel treatment systems.

Home Healthcare

Home healthcare is expected to register the highest growth rate among end-user segments through 2035.

Home HD programs can reduce patient travel and provide greater scheduling flexibility, but they transfer operational responsibilities from trained dialysis-center staff toward patients and caregivers. Device design is therefore critical.

Systems that minimize manual connections, simplify setup, automate cleaning, reduce water requirements, support remote monitoring, and offer rapid technical assistance will have the strongest commercial position.

Nephrology and Specialty Renal Centers

Independent nephrology groups, transitional-care units, specialized kidney centers, and other renal-care organizations represent a smaller but strategically relevant segment.

These settings may support dialysis education, urgent-start programs, patient transition, home-training programs, and specialized treatment models.

Manufacturers can use these centers to demonstrate differentiated workflows before pursuing larger enterprise agreements.

Regional Insights: Where the Market is Growing Fastest

The U.S. Hemodialysis Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance varies according to ESKD prevalence, diabetes and hypertension burden, age structure, population growth, dialysis-center density, rural access, home-dialysis penetration, hospital infrastructure, payer mix, and adoption of newer treatment technologies.

The South represents the largest regional market, while the West is expected to record the fastest percentage growth through 2035. The Midwest retains a large mature installed base, while the Northeast remains important for academic nephrology, advanced treatment adoption, and clinical evaluation.

South

The South accounted for an estimated USD 2.20 billion in 2025, representing approximately 39% of the national hemodialysis-device market. At its current trajectory, regional revenue could approach USD 4.89 billion by 2035.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, West Virginia, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, and Oklahoma.

The South’s leadership is structurally important rather than temporary. Several Southern states combine high diabetes prevalence, hypertension, obesity, cardiovascular risk, large minority populations disproportionately affected by ESKD, rural healthcare-access limitations, and rapidly growing populations. These factors create sustained demand for maintenance dialysis.

Texas is one of the most important hemodialysis-device markets in the United States. The state combines a population exceeding 30 million residents with large metropolitan healthcare markets in Houston, Dallas-Fort Worth, San Antonio, and Austin. Major dialysis organizations maintain extensive treatment-center networks across the state. Texas therefore offers significant demand for dialysis machines, dialyzers, bloodlines, access devices, and water-treatment equipment.

The state’s large geographic footprint is also relevant. Patients in rural areas may face substantial transportation requirements for thrice-weekly in-center dialysis. As home-capable technology improves, Texas could become an important expansion market for decentralized HD models.

Florida is another critical state because of its large older-adult population. Aging increases the prevalence of diabetes, hypertension, cardiovascular disease, and advanced CKD. Florida also contains extensive outpatient dialysis infrastructure distributed across Miami, Tampa, Orlando, Jacksonville, Southwest Florida, and numerous retirement communities.

The state’s demographic profile creates strong recurring consumption of hemodialysis disposables and supports opportunities for home-treatment platforms among appropriately selected patients.

Georgia has one of the larger dialysis-center footprints in the South, with Atlanta serving as a major referral and nephrology hub. High CKD risk burden across parts of the state supports substantial treatment demand. Georgia is strategically important for vendors selling vascular-access products because patients with diabetes and vascular disease frequently require intensive access management.

North Carolina combines growing population centers, strong academic healthcare institutions, major integrated health systems, and a significant chronic-disease burden. Research and clinical capabilities at large centers can support early evaluation of newer dialysis technology, while community dialysis networks create scale for mature consumables.

Virginia and Maryland benefit from dense health-system networks and relatively sophisticated payer markets. Northern Virginia, Richmond, Baltimore, and surrounding metropolitan areas provide substantial dialysis capacity. These markets are likely to be receptive to connected treatment systems where interoperability and clinical-data integration are demonstrable.

Tennessee and Kentucky have established renal-care infrastructure and substantial diabetes and cardiovascular-disease burden. Nashville additionally serves as an important healthcare-services headquarters market, giving manufacturers access to corporate healthcare decision-makers as well as clinical customers.

Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and West Virginia represent particularly important markets from a disease-burden perspective. Rural access and social determinants can complicate early CKD management and transportation to dialysis.

These states present a dual commercial opportunity. Larger metropolitan centers support conventional facility-based equipment, while rural areas create a stronger strategic rationale for home treatment, remote monitoring, smaller treatment sites, and machines requiring less fixed infrastructure.

The South should remain the largest U.S. regional market through 2035. Growth will be driven by population expansion, continuing ESKD burden, machine-fleet replacement, increased home-treatment activity, and eventual diffusion of HDF into major dialysis networks.

West

The West represented an estimated USD 1.19 billion in 2025 and is projected to expand to approximately USD 2.84 billion by 2035, making it the fastest-growing region at an estimated CAGR of around 9.1%.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is by far the largest state market in the West and one of the largest nationally. Its importance derives from population scale, high dialysis-facility density, major academic health systems, a large technology sector, and substantial socioeconomic and demographic diversity.

California is particularly relevant for newer dialysis platforms because health systems and renal-care organizations have access to clinical engineering, connected-health infrastructure, venture-backed technology ecosystems, and sophisticated home-care programs.

The state also illustrates the operational pressures facing dialysis providers. High labor costs create a strong economic incentive for automation. Technologies that reduce technician workload, automate machine preparation, simplify disinfection, or allow treatment capacity to expand without proportional labor growth may create greater value in California than in lower-cost states.

Arizona and Nevada are attractive growth markets because both have experienced rapid population expansion and growing older-adult populations. Migration from other states adds patients already receiving chronic dialysis, requiring local providers to expand capacity.

Arizona’s Phoenix and Tucson markets support large health-system and dialysis networks. Nevada’s growth is concentrated particularly around Las Vegas and Reno. Home dialysis may become increasingly important as suburban development increases travel distances from treatment facilities.

Washington and Oregon have relatively mature healthcare systems with strong interest in connected care, population-health management, and evidence-based procurement. Seattle and Portland provide important nephrology and academic-care ecosystems.

The region’s technology orientation can favor devices with sophisticated software, remote monitoring, analytics, and interoperability rather than purely hardware-based differentiation.

Colorado and Utah combine population growth with strong integrated delivery networks. Denver and Salt Lake City are important regional medical hubs, and both states have broad rural catchment areas. Compact systems that can support satellite treatment centers or home dialysis may therefore have particular relevance.

New Mexico, Idaho, Montana, and Wyoming are smaller markets by absolute value but highlight the access problem created by geographic dispersion. Patients in sparsely populated communities may travel long distances for dialysis. Home HD and smaller-footprint treatment platforms could address part of this unmet logistical burden, provided training and broadband-supported remote care are available.

Alaska and Hawaii represent unique dialysis economics because transportation, equipment servicing, utilities, shipping, and supply-chain requirements are substantially different from those in the continental United States. CMS payment policy recognizes higher non-labor operating costs in non-contiguous areas. Manufacturers serving these markets require particularly robust logistics and field-service models.

The West’s above-market growth through 2035 will be driven by population migration, home-dialysis technology, automation, digital connectivity, compact treatment platforms, and early adoption of newer dialysis modalities.

Northeast

The Northeast accounted for approximately USD 1.11 billion in 2025 and could reach around USD 2.36 billion by 2035.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire, Maine, and Delaware.

The Northeast is a mature dialysis market, but it remains strategically important because of the concentration of academic medical centers, nephrology specialists, research institutions, hospital systems, and complex patients.

New York represents the largest state market in the region. New York City alone contains a dense network of hospitals, outpatient dialysis centers, nursing facilities, and nephrology practices. Upstate markets including Buffalo, Rochester, Syracuse, and Albany add substantial additional demand.

High labor expenses and limited physical space within metropolitan facilities make compact machine footprints, automation, and throughput efficiency especially relevant. Manufacturers that reduce station-level operational burden may therefore command greater interest even in a relatively mature treatment market.

Pennsylvania provides one of the region’s largest dialysis populations and benefits from major healthcare markets in Philadelphia and Pittsburgh. The state also contains large rural areas, producing different purchasing requirements between urban academic systems and community dialysis networks.

New Jersey has high population density and significant dialysis demand along the New York and Philadelphia metropolitan corridors. Enterprise procurement by large dialysis organizations plays an important role in the state.

Massachusetts is disproportionately influential relative to its population because of its academic and biotechnology ecosystem. Boston-based medical institutions can contribute to clinical research, adoption of emerging renal technology, and evidence generation.

Advanced membranes, HDF, digital monitoring, and novel dialysis-system designs may gain early evaluation in these institutions before wider commercial adoption.

Connecticut, Rhode Island, New Hampshire, Vermont, Maine, and Delaware are smaller state markets. Their demand is driven primarily by mature outpatient dialysis infrastructure, aging populations in selected areas, and regional health-system networks.

Northern New England creates opportunities for home treatment because of geographic dispersion and travel burden, whereas southern New England is characterized by greater facility density.

Regional growth will likely remain below the West because population expansion is slower and the existing dialysis infrastructure is mature. Nevertheless, high labor costs, concentration of academic centers, and sophisticated purchasing committees create strong potential for premium technologies that provide measurable workflow or clinical improvement.

Midwest

The Midwest accounted for approximately USD 1.12 billion in 2025 and is projected to reach approximately USD 2.41 billion by 2035.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota, and South Dakota.

The Midwest provides a large, stable dialysis-treatment base supported by metropolitan health systems, community dialysis networks, and significant chronic-disease prevalence.

Illinois is the largest regional state market, with Chicago providing a major concentration of hospitals, dialysis centers, nephrology groups, and academic institutions. The state’s large urban population supports substantial recurring demand for dialyzers and extracorporeal consumables.

Ohio is another major dialysis-device market, with strong healthcare capacity in Cleveland, Columbus, Cincinnati, Dayton, and other metropolitan areas. Large integrated provider organizations and academic hospitals make Ohio relevant for both mature HD products and newer technologies.

Michigan has significant chronic-kidney-disease and cardiovascular-risk burden and supports substantial dialysis activity across Detroit, Grand Rapids, Lansing, Flint, and surrounding communities.

Minnesota has strategic importance beyond its population size because of its medical-device ecosystem and history in dialysis technology. The state contains major health systems and sophisticated clinical organizations capable of evaluating advanced renal technologies.

Indiana and Wisconsin represent stable, high-volume markets dominated by conventional outpatient dialysis but with growing interest in home therapies and workflow efficiency.

Missouri, Iowa, and Kansas contain both metropolitan treatment hubs and broad rural populations. Kansas City and St. Louis operate as regional referral markets, while more dispersed areas face travel-access challenges.

Nebraska, North Dakota, and South Dakota are smaller in absolute device revenue but important test cases for decentralized kidney care. Rural patients can face substantial travel requirements for maintenance dialysis. Expanding home HD eligibility and improving remote monitoring could meaningfully alter treatment economics in these states.

The Midwest is not expected to outpace the West or South, but it offers predictable consumable volumes and large replacement opportunities. Manufacturers are likely to succeed through service reliability, clinically credible products, favorable contracting, staff training, and clear lifecycle economics rather than premium technology positioning alone.

Key Market Players

The U.S. Hemodialysis Devices Competitive Landscape is concentrated at the top of the market but becoming more dynamic as newer machine platforms enter commercial use.

Fresenius Medical Care possesses the broadest strategic position because it participates across dialysis machines, dialyzers, bloodlines, home hemodialysis, dialysis services, and related renal technologies. Globally, the company reports leadership positions in both HD machines and dialyzers, giving it substantial manufacturing scale and consumables leverage.

Vantive became an independent kidney and vital-organ therapy company in 2025 following separation of Baxter’s former Kidney Care business. Its inherited renal portfolio provides an established position across chronic and acute dialysis technologies.

Outset Medical, Quanta Dialysis Technologies, Diality, and Nikkiso represent strategically important equipment competitors because their systems introduce alternative architectures centered on simplification, automation, compact design, or home treatment.

Vascular-access and consumables competition is considerably more fragmented, with companies such as BD, Teleflex, Merit Medical Systems, AngioDynamics, Medline, and Cardinal Health participating across catheters, needles, tubing, and associated supplies.

Some of the key players operating in or supplying the U.S. hemodialysis-device ecosystem include:

Fresenius Medical Care
Vantive
B. Braun Medical Inc.
Nipro Medical Corporation
Nikkiso Co., Ltd.
Outset Medical, Inc.
Quanta Dialysis Technologies
Diality, Inc.
Toray Medical Co., Ltd.
Asahi Kasei Medical
Mozarc Medical
BD
Teleflex Incorporated
Merit Medical Systems, Inc.
AngioDynamics, Inc.
Cook Medical
ICU Medical, Inc.
Rockwell Medical, Inc.
Medline Industries, LP
Cardinal Health, Inc.
STERIS plc
Xylem Inc.
DaVita Inc.
U.S. Renal Care

Competitive differentiation through 2035 will increasingly depend on the ability to control more of the treatment ecosystem. A manufacturer supplying machines, disposable circuits, dialyzers, fluid systems, software, remote monitoring, service, and clinical training has considerably more contracting leverage than a supplier offering a single undifferentiated product.

However, newer companies can gain share when they solve a specific workflow problem ignored by incumbent platforms. Home usability, machine portability, automated setup, water independence, treatment-data connectivity, and alternative economic models remain meaningful entry points.

Supply resilience will also affect competitive positioning. Because dialysis treatment cannot be postponed indefinitely, shortages of dialyzers, bloodlines, concentrates, or machine service can immediately affect provider operations. Large customers will therefore continue to place substantial weight on manufacturing capacity, redundant supply chains, field service, and quality-system performance.

Recent Developments

Recent developments indicate that the U.S. hemodialysis market is entering one of its more active equipment-innovation periods in decades.

A major development was the progression of high-volume hemodiafiltration technology into the U.S. market. Fresenius Medical Care received FDA clearance in 2025 for an updated version of its 5008X hemodialysis system. Initial HDF treatments subsequently began within selected U.S. Fresenius Kidney Care facilities, with broader commercialization planned.

The significance of this development extends beyond one manufacturer’s machine sales. Broader HDF adoption could accelerate replacement of conventional HD equipment, increase requirements for compatible bloodlines and dialyzers, raise the importance of ultrapure water management, and create a new clinical differentiation strategy for U.S. dialysis providers.

Another important equipment development was FDA clearance of Nikkiso’s DBB-06 PRO Hemodialysis Delivery System in May 2025. The system incorporates automation designed to reduce manual treatment-preparation tasks. This represents a wider industry movement toward machine designs that address labor economics in addition to clinical performance.

Quanta Dialysis Technologies strengthened competition in home hemodialysis when the SC+ Hemodialysis Device received FDA clearance for home use in November 2024. The platform’s transition from facility-based to home-capable treatment expands provider choice and reinforces the commercial opportunity for systems that simplify HD sufficiently for patient-operated environments.

Diality also entered the competitive equipment landscape through FDA clearance of its Moda-flx Hemodialysis System in August 2024. The emergence of additional platforms is strategically meaningful because U.S. dialysis-machine purchasing has historically been concentrated among relatively few manufacturers.

Outset Medical continued to develop its Tablo platform across facility and home settings. FDA records show additional clearance activity extending into 2026, reflecting continuing product development. At the same time, safety corrections and recalls affecting dialysis equipment across the industry highlight the importance of materials, software validation, manufacturing control, and post-market quality management.

Reimbursement policy has also evolved. Beginning in 2025, Medicare expanded payment availability for dialysis furnished at home to qualifying beneficiaries with acute kidney injury and permitted home/self-dialysis training adjustments in those circumstances. Although the immediate addressable population is smaller than chronic ESKD, the policy reinforces a broader direction toward site-of-care flexibility.

The corporate landscape changed materially when Baxter completed the sale of its Kidney Care business to Carlyle in January 2025 for approximately USD 3.8 billion, creating Vantive as a standalone company. The transaction gives the former Baxter renal portfolio an independent strategic identity focused specifically on kidney and vital-organ therapies.

During the remainder of the forecast period, market development is expected to concentrate around HDF commercialization, home HD expansion, automated dialysis workflows, connected equipment, new membrane technologies, water-efficiency improvements, and integration of machine data into provider operating systems.

Conclusion

The U.S. Hemodialysis Devices Market Size & Share is positioned to expand from approximately USD 5.62 billion in 2025 to USD 12.50 billion by 2035, representing a CAGR of 8.32% during 2026–2035.

The long-term strength of the market is supported by an unusually durable clinical need. Hundreds of thousands of Americans depend on hemodialysis, and each active patient generates repeated consumption of dialyzers, bloodlines, access products, concentrates, and machine capacity throughout the year.

However, the next decade will not simply be a higher-volume version of the existing market.

The competitive value pool is shifting toward high-volume hemodiafiltration, home-capable machines, compact dialysis platforms, automation, digitally connected equipment, advanced membranes, simplified fluid management, and integrated recurring-consumables ecosystems.

For dialysis providers, the most attractive technology will increasingly be the technology that improves the economics of the entire treatment station. Nursing time, technician workload, consumables waste, water utilization, machine uptime, treatment throughput, supply reliability, home-training burden, and avoidable complications all affect purchasing decisions.

Regionally, the South will remain the largest U.S. hemodialysis-device market, driven by population scale and kidney-disease burden. The West is expected to deliver the fastest growth, supported by demographic expansion, technology adoption, home-treatment interest, and high labor costs that improve the business case for automation. The Midwest will provide a durable installed base, while the Northeast will remain important for advanced clinical adoption and academic evaluation.

Fresenius Medical Care remains the strongest vertically integrated competitor, but the emergence of Outset Medical, Quanta, Diality, Nikkiso, and other technology providers is expanding equipment choice. Vantive’s creation as a standalone renal-therapy company also changes the strategic structure of the supplier ecosystem.

For manufacturers, investors, distributors, health systems, and dialysis organizations evaluating this market, the central question is therefore not whether U.S. hemodialysis demand will continue.

The more important questions are which treatment platform will control the next machine-replacement cycle, how quickly HDF will penetrate U.S. dialysis centers, whether home HD can move beyond its current niche, which suppliers can convert installed equipment into recurring consumables revenue, and how much providers will pay for technologies that demonstrably lower treatment-delivery cost.

Companies capable of combining clinical credibility, manufacturing scale, reliable disposable supply, workflow automation, reimbursement understanding, service infrastructure, and measurable treatment economics will be best positioned to capture the next decade of value creation in the U.S. hemodialysis devices industry.

TABLE OF CONTENT

1. U.S. Hemodialysis Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Hemodialysis Machine and System Manufacturers
1.6.2. Dialyzer and Membrane Manufacturers
1.6.3. Bloodline, Tubing, Cartridge and Consumable Suppliers
1.6.4. Vascular Access Device Manufacturers
1.6.5. Outpatient Dialysis Organizations and ESRD Facilities
1.6.6. Hospitals, Health Systems and Academic Medical Centers
1.6.7. Home Hemodialysis Providers and Patient Support Networks
1.6.8. Group Purchasing Organizations and Medical Distributors
1.6.9. Nephrologists, Clinical Decision-Makers and Dialysis Nursing Teams
1.6.10. CMS, Commercial Payers and Regulatory Authorities

What this section provides: This section defines the U.S. hemodialysis devices market boundary, study scope, research methodology, assumptions, device ecosystem, and stakeholder structure so clients understand how equipment, consumables, treatment platforms, and commercial demand are measured and validated.

2. U.S. Hemodialysis Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Growth Trajectory, 2021–2035
2.8. High-Growth Opportunity Areas
2.8.1. Home Hemodialysis Devices
2.8.2. High-Volume Hemodiafiltration Systems
2.8.3. Automated Hemodialysis Platforms
2.8.4. High-Flux and Advanced Dialyzer Membranes
2.8.5. Digitally Connected Dialysis Systems
2.8.6. Water-Efficient Dialysis Technologies

What this section provides: This section gives decision-makers a concise view of market size, historical development, 2025 positioning, 2026–2035 growth potential, technology shifts, competitive intensity, and priority commercial opportunities.

3. U.S. Hemodialysis Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Large and Persistent U.S. End-Stage Kidney Disease Burden
3.1.2. Recurring Hemodialysis Treatment and Consumable Demand
3.1.3. Rising Diabetes, Hypertension and Chronic Kidney Disease Burden
3.1.4. Aging U.S. Dialysis Population
3.1.5. Expansion of Home Hemodialysis
3.1.6. Replacement and Modernization of Hemodialysis Machine Fleets
3.1.7. Dialysis Staffing Constraints and Demand for Workflow Automation
3.1.8. Growing Adoption of High-Flux Dialysis and Hemodiafiltration
3.1.9. Increasing Demand for Digitally Connected Dialysis Care

3.2. Restraints and Their Impact Analysis
3.2.1. High Capital and Recurring Treatment Costs
3.2.2. ESRD Bundled Reimbursement and Provider Cost Pressure
3.2.3. High Clinical Training Requirements for Home Hemodialysis
3.2.4. Dialysis Machine Recalls and Product Safety Risks
3.2.5. Vascular Access Complications
3.2.6. Concentrated Dialysis Provider Purchasing Power
3.2.7. Water Infrastructure and Facility Installation Requirements

3.3. Opportunities and Their Impact Analysis
3.3.1. High-Volume Hemodiafiltration Adoption
3.3.2. Next-Generation Home Hemodialysis Platforms
3.3.3. Portable and Compact Dialysis Systems
3.3.4. Automated Priming, Setup, Disinfection and Documentation
3.3.5. Advanced High-Flux and Medium Cut-Off Dialyzers
3.3.6. Remote Treatment Monitoring and Connected Dialysis
3.3.7. Predictive Machine Maintenance and Fleet Analytics
3.3.8. Water-Efficient and On-Demand Dialysate Systems
3.3.9. Expansion into Rural and Underserved Dialysis Markets

3.4. Challenges and Their Impact Analysis
3.4.1. Dialysis Nursing and Technician Workforce Shortages
3.4.2. Home Patient Training and Retention
3.4.3. Supply Continuity for Critical Consumables
3.4.4. Equipment Service and Machine Uptime Requirements
3.4.5. Cybersecurity and Connected Device Risks
3.4.6. Converting Clinical Innovation into Provider-Level Economic Value

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Hemodialysis Clinical Workflow Economics Analysis
3.7. Dialysis Center Capital Procurement Behavior Analysis
3.8. Consumables Attachment and Installed-Base Economics
3.9. Home Hemodialysis Economic Model Analysis

What this section provides: This section explains the epidemiological, clinical, operational, reimbursement, technological, and commercial forces shaping U.S. hemodialysis-device demand and helps clients evaluate upside potential, adoption barriers, workflow economics, and execution risks.

4. U.S. Hemodialysis Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Large Dialysis Organizations
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Hemodialysis Machine Installed-Base and Replacement Cycle Analysis
4.6. Disposable and Recurring Consumables Revenue Model
4.7. Impact of Digitalization and Connected Dialysis Care
4.8. Application & Innovation Landscape
4.9. FDA Regulatory Framework Analysis
4.10. CMS ESRD Prospective Payment System Analysis
4.11. Medicare Home Dialysis Reimbursement Landscape
4.12. Medicare and Commercial Payer Coverage Dynamics
4.13. Import/Export Restrictions & Tariff Impact
4.14. U.S. Kidney Health Programs and Government Initiatives
4.15. Environmental Sustainability and Dialysis Water Consumption Analysis
4.16. Impact of Escalating Geopolitical Tensions
4.17. Dialysis Provider Value Analysis and Procurement Decision Framework
4.18. Large Dialysis Organization Enterprise Contracting Analysis

What this section provides: This section gives clients a complete view of the external market environment, including reimbursement, FDA regulation, pricing, dialysis-provider concentration, supply chains, installed-machine economics, environmental considerations, technology adoption, and procurement behavior.

5. U.S. Hemodialysis Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)

5.1.2. Hemodialysis Machines

5.1.2.1. Conventional In-Center Hemodialysis Machines
5.1.2.2. Compact and Portable Hemodialysis Machines
5.1.2.3. Home Hemodialysis Machines
5.1.2.4. Hemodiafiltration-Capable Machines
5.1.2.5. Acute and Multipurpose Hemodialysis Systems

5.1.3. Dialyzers

5.1.3.1. High-Flux Dialyzers
5.1.3.2. Low-Flux Dialyzers
5.1.3.3. High-Performance Synthetic Membrane Dialyzers
5.1.3.4. Medium Cut-Off and Expanded Hemodialysis Dialyzers
5.1.3.5. Hemodiafiltration-Compatible Dialyzers

5.1.4. Bloodline Systems, Tubing Sets and Treatment Cartridges

5.1.4.1. Arterial Bloodlines
5.1.4.2. Venous Bloodlines
5.1.4.3. Integrated Blood Tubing Sets
5.1.4.4. Machine-Specific Treatment Cartridges
5.1.4.5. Single-Use Extracorporeal Circuit Components

5.1.5. Vascular Access Devices

5.1.5.1. Arteriovenous Fistula Needles
5.1.5.2. Tunneled Hemodialysis Catheters
5.1.5.3. Non-Tunneled Dialysis Catheters
5.1.5.4. Catheter Accessories and Securement Products
5.1.5.5. Dialysis Access Maintenance Devices

5.1.6. Dialysate Concentrates, Water-Treatment Systems and Other Consumables

5.1.6.1. Acid Concentrates
5.1.6.2. Bicarbonate Concentrates
5.1.6.3. Reverse Osmosis and Water Purification Systems
5.1.6.4. Ultrafilters and Water-Treatment Consumables
5.1.6.5. Disinfection and Cleaning Products
5.1.6.6. Other Hemodialysis Consumables

What this section provides: This section identifies the hemodialysis product categories expected to generate the largest recurring revenue, strongest equipment replacement opportunity, fastest consumables growth, and highest technology-driven expansion through 2035.

6. U.S. Hemodialysis Devices Market – By Treatment Modality & Technology

6.1. Overview
6.1.1. Segment Share Analysis, By Treatment Modality & Technology, 2025 & 2035 (%)

6.1.2. Conventional In-Center Hemodialysis

6.1.2.1. Standard Three-Times-Weekly Hemodialysis
6.1.2.2. Extended In-Center Hemodialysis
6.1.2.3. In-Center Nocturnal Hemodialysis

6.1.3. High-Flux Hemodialysis

6.1.3.1. Conventional High-Flux Hemodialysis
6.1.3.2. Enhanced Middle-Molecule Clearance Hemodialysis

6.1.4. High-Volume Hemodiafiltration

6.1.4.1. Online Hemodiafiltration
6.1.4.2. Post-Dilution Hemodiafiltration
6.1.4.3. Pre-Dilution and Mixed-Dilution Hemodiafiltration

6.1.5. Home Hemodialysis

6.1.5.1. Conventional Home Hemodialysis
6.1.5.2. Short Daily Home Hemodialysis
6.1.5.3. Nocturnal Home Hemodialysis
6.1.5.4. Portable and Cartridge-Based Home Hemodialysis

6.1.6. Acute and Extended Hemodialysis Therapies

6.1.6.1. Intermittent Hemodialysis
6.1.6.2. Sustained Low-Efficiency Dialysis
6.1.6.3. Prolonged Intermittent Renal Replacement Therapy

What this section provides: This section evaluates conventional HD, high-flux dialysis, HDF, home HD, and acute treatment technologies to identify which treatment platforms are most likely to drive machine replacement, premium consumables demand, and procedural transformation through 2035.

7. U.S. Hemodialysis Devices Market – By Clinical Application

7.1. Overview
7.1.1. Segment Share Analysis, By Clinical Application, 2025 & 2035 (%)

7.1.2. Chronic End-Stage Kidney Disease

7.1.2.1. Diabetic Kidney Disease-Associated ESKD
7.1.2.2. Hypertension-Associated ESKD
7.1.2.3. Glomerular and Other Chronic Kidney Disorders
7.1.2.4. Long-Term Maintenance Hemodialysis

7.1.3. Acute Kidney Injury

7.1.3.1. Hospital-Acquired Acute Kidney Injury
7.1.3.2. ICU-Associated Acute Kidney Injury
7.1.3.3. Post-Acute Dialysis-Dependent AKI
7.1.3.4. Home-Based AKI Dialysis in Eligible Patients

7.1.4. Cardiorenal and Fluid-Overload Management

7.1.4.1. Heart Failure-Associated Fluid Overload
7.1.4.2. Cardiorenal Syndrome
7.1.4.3. Refractory Volume Overload

7.1.5. Complex and High-Acuity Renal Failure

7.1.5.1. Critically Ill Patients
7.1.5.2. Hemodynamically Vulnerable Patients
7.1.5.3. Hospitalized Chronic Dialysis Patients

7.1.6. Pediatric Hemodialysis

7.1.6.1. Chronic Pediatric Kidney Failure
7.1.6.2. Acute Pediatric Renal Failure
7.1.6.3. Adolescent Maintenance Hemodialysis

What this section provides: This section helps clients understand device demand by clinical use case and identify application areas where patient volume, treatment intensity, complication burden, reimbursement, and technology requirements create attractive commercial opportunities.

8. U.S. Hemodialysis Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

8.1.2. Outpatient Dialysis Centers

8.1.2.1. Large Dialysis Organization Facilities
8.1.2.2. Independent Dialysis Centers
8.1.2.3. Hospital-Affiliated Outpatient Dialysis Centers

8.1.3. Hospitals and Health Systems

8.1.3.1. Academic Medical Centers
8.1.3.2. Tertiary and Quaternary Hospitals
8.1.3.3. Community Hospitals
8.1.3.4. Intensive Care and Acute Dialysis Departments

8.1.4. Home Healthcare and Patient Homes

8.1.4.1. Self-Care Home Hemodialysis
8.1.4.2. Caregiver-Assisted Home Hemodialysis
8.1.4.3. Remote-Supported Home Dialysis Programs

8.1.5. Nephrology and Specialty Renal Centers

8.1.5.1. Independent Nephrology Practices
8.1.5.2. Transitional Kidney Care Centers
8.1.5.3. Home Dialysis Training Centers
8.1.5.4. Specialized Renal Therapy Centers

8.1.6. Skilled Nursing and Post-Acute Care Facilities

8.1.6.1. Skilled Nursing Facilities
8.1.6.2. Long-Term Acute Care Hospitals
8.1.6.3. Rehabilitation and Post-Acute Facilities

What this section provides: This section explains which U.S. care settings drive machine placement, disposable utilization, home-dialysis adoption, treatment volume, and procurement decisions, enabling clients to prioritize the highest-value customer groups.

9. U.S. Hemodialysis Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)

9.1.2. Direct Manufacturer Procurement

9.1.2.1. Equipment Purchase Agreements
9.1.2.2. Machine Lease and Placement Agreements
9.1.2.3. Service and Maintenance Contracts

9.1.3. Large Dialysis Organization and Enterprise Contracts

9.1.3.1. Multi-Site Machine Standardization Agreements
9.1.3.2. Dialyzer and Consumables Supply Agreements
9.1.3.3. Integrated Equipment-Consumables Contracts
9.1.3.4. National and Regional Fleet Agreements

9.1.4. Group Purchasing Organization Contracts

9.1.4.1. Hospital GPO Procurement
9.1.4.2. Integrated Delivery Network Purchasing
9.1.4.3. Regional Purchasing Cooperatives

9.1.5. Distributor and Specialty Supplier Sales

9.1.5.1. National Medical Distributors
9.1.5.2. Specialty Renal Product Distributors
9.1.5.3. Vascular Access and Consumables Distributors

9.1.6. Home Hemodialysis Program Procurement

9.1.6.1. Provider-Supplied Home Equipment
9.1.6.2. Recurring Home Consumable Supply
9.1.6.3. Direct-to-Patient Logistics and Delivery
9.1.6.4. Remote Technical Support and Service Programs

What this section provides: This section explains how hemodialysis machines and recurring consumables are purchased in the U.S., including enterprise dialysis-provider contracts, manufacturer placement models, GPO influence, distribution, and home-dialysis procurement.

10. U.S. Hemodialysis Devices Market – By Geography
10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Hemodialysis Patient and Treatment Volume Analysis
10.1.4. Regional ESRD Facility and Dialysis Infrastructure Analysis
10.1.5. Regional Diabetes, CKD and ESKD Burden Analysis
10.1.6. Regional Home Hemodialysis Adoption Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Hemodialysis Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Hemodialysis Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Hemodialysis Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Hemodialysis Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Treatment Modality & Technology, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By Clinical Application, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed four-region and 50-state analysis, helping clients identify U.S. dialysis-demand concentrations, ESRD treatment hubs, home-hemodialysis opportunities, disease-burden hotspots, equipment replacement opportunities, and state-level commercial priorities.

11. U.S. Hemodialysis Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Hemodialysis Machine Market Share
11.1.2. Dialyzer Market Share
11.1.3. Disposable and Consumables Market Share
11.1.4. Vascular Access Product Competitive Positioning

11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players

11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. U.S. Installed Machine Base
11.3.3. Consumables Attachment Strategy
11.3.4. Home Hemodialysis Positioning
11.3.5. Hemodiafiltration Capability
11.3.6. Digital and Connected Dialysis Capabilities
11.3.7. Service and Maintenance Infrastructure
11.3.8. U.S. Distribution and Contracting Strength

11.4. Company Profiles

11.4.1. Fresenius Medical Care
11.4.2. Vantive
11.4.3. B. Braun Medical Inc.
11.4.4. Nipro Medical Corporation
11.4.5. Nikkiso Co., Ltd.
11.4.6. Outset Medical, Inc.
11.4.7. Quanta Dialysis Technologies
11.4.8. Diality, Inc.
11.4.9. Toray Medical Co., Ltd.
11.4.10. Asahi Kasei Medical Co., Ltd.
11.4.11. Mozarc Medical
11.4.12. BD
11.4.13. Teleflex Incorporated
11.4.14. Merit Medical Systems, Inc.
11.4.15. AngioDynamics, Inc.
11.4.16. Cook Medical
11.4.17. ICU Medical, Inc.
11.4.18. Rockwell Medical, Inc.
11.4.19. Medline Industries, LP
11.4.20. Cardinal Health, Inc.
11.4.21. Medical Components, Inc. (Medcomp)
11.4.22. JMS North America Corporation
11.4.23. Argon Medical Devices, Inc.
11.4.24. Xylem Inc.
11.4.25. STERIS plc

11.5. Company Profile Coverage Framework
11.5.1. Company Overview
11.5.2. Hemodialysis Device Portfolio
11.5.3. U.S. Market Positioning
11.5.4. Machine and Consumables Strategy
11.5.5. Home Hemodialysis Strategy
11.5.6. Financial Positioning
11.5.7. Clinical and Technology Pipeline
11.5.8. FDA Regulatory Updates
11.5.9. Partnerships, Agreements and Collaborations
11.5.10. Mergers, Acquisitions and Portfolio Expansion
11.5.11. Recent Developments

What this section provides: This section gives clients competitor benchmarking, market-share visibility, installed-base positioning, recurring consumables strategies, home-HD capabilities, innovation direction, and strategic intelligence on major companies participating in the U.S. hemodialysis-device ecosystem.

12. U.S. Hemodialysis Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact

12.2.1. High-Volume Hemodiafiltration
12.2.1.1. U.S. Clinical Adoption Potential
12.2.1.2. Machine Replacement Impact
12.2.1.3. Dialyzer and Consumables Impact

12.2.2. Home and Portable Hemodialysis
12.2.2.1. Patient Self-Care Platforms
12.2.2.2. Compact and Cartridge-Based Systems
12.2.2.3. Remote Home Treatment Support

12.2.3. Automated Hemodialysis Workflow
12.2.3.1. Automated Priming
12.2.3.2. Automated Rinse-Back
12.2.3.3. Automated Disinfection
12.2.3.4. Prescription and Treatment Documentation Automation

12.2.4. Advanced Dialyzer Membranes
12.2.4.1. High-Flux Membranes
12.2.4.2. Medium Cut-Off Membranes
12.2.4.3. Expanded Hemodialysis Technologies

12.2.5. Connected Dialysis and Predictive Analytics
12.2.5.1. Remote Device Monitoring
12.2.5.2. Treatment Data Connectivity
12.2.5.3. Predictive Equipment Maintenance
12.2.5.4. AI-Assisted Treatment Workflow

12.2.6. Water-Efficient Hemodialysis
12.2.6.1. Reduced-Water Dialysis Systems
12.2.6.2. On-Demand Dialysate Generation
12.2.6.3. Portable Water Purification

12.3. Future Machine Replacement Cycle Analysis
12.4. Future Dialyzer and Consumables Mix Analysis
12.5. Emerging Business Trends
12.6. Shift from Capital Equipment Sales to Platform Economics
12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. Technology Commercialization Readiness Matrix

What this section provides: This section prepares clients for technology transitions, machine-replacement cycles, HDF penetration, home-HD expansion, automation, membrane innovation, connected care, and business-model changes expected to reshape the U.S. hemodialysis devices market through 2035.

13. U.S. Hemodialysis Devices Market: Strategic Recommendations

13.1. Recommendations for Hemodialysis Device Manufacturers
13.1.1. Machine Portfolio Strategy
13.1.2. Consumables Attachment Strategy
13.1.3. HDF Commercialization Strategy
13.1.4. Home Hemodialysis Expansion Strategy
13.1.5. Digital Connectivity Strategy

13.2. Recommendations for Dialysis Organizations and ESRD Facilities
13.2.1. Machine Replacement Planning
13.2.2. Workflow Automation Assessment
13.2.3. Total Treatment Cost Evaluation
13.2.4. HDF Adoption Assessment
13.2.5. Home Hemodialysis Program Expansion

13.3. Recommendations for Hospitals and Health Systems
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.7.1. Large Dialysis Organization Contracting
13.7.2. Hospital Market Entry
13.7.3. Home Dialysis Commercialization
13.7.4. Distributor-Led Market Access
13.7.5. Clinical Evidence Development

13.8. Product Positioning and Portfolio Expansion Guidance
13.9. Pricing and Contracting Strategy
13.10. U.S. State Prioritization Strategy
13.11. Partnership and Acquisition Opportunity Assessment

What this section provides: This section converts U.S. hemodialysis market intelligence into actionable strategies for product development, capital-equipment positioning, recurring consumables growth, HDF commercialization, home-HD expansion, contracting, distribution, investment, and competitive differentiation.

14. U.S. Hemodialysis Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing Limitation
14.4. Forecasting Limitation
14.5. State-Level Estimate Limitation
14.6. Regulatory and Reimbursement Information Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope boundaries, market-sizing limitations, state-level modeling considerations, forecasting assumptions, regulatory and reimbursement limitations, legal terms, and third-party data-use conditions.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Hemodialysis Devices Market: Market Definition and Scope
TABLE 3: U.S. Hemodialysis Devices Market: Research Methodology Framework
TABLE 4: U.S. Hemodialysis Devices Market: Key Assumptions
TABLE 5: U.S. Hemodialysis Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Hemodialysis Devices Market: Stakeholder Analysis
TABLE 7: U.S. Hemodialysis Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Hemodialysis Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Hemodialysis Devices Market: Market Attractiveness Index
TABLE 10: U.S. Hemodialysis Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Hemodialysis Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Hemodialysis Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Hemodialysis Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Hemodialysis Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Hemodialysis Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Hemodialysis Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Hemodialysis Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Hemodialysis Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Hemodialysis Devices Market: Dialysis Center Capital Procurement Behavior Matrix
TABLE 20: U.S. Hemodialysis Devices Market: Consumables Attachment and Installed-Base Economics
TABLE 21: U.S. Hemodialysis Devices Market: Home Hemodialysis Economic Model
TABLE 22: U.S. Hemodialysis Devices Market: PESTEL Analysis
TABLE 23: U.S. Hemodialysis Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Hemodialysis Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Hemodialysis Devices Market: Value Chain Analysis
TABLE 26: U.S. Hemodialysis Devices Market: Supply Chain Analysis
TABLE 27: U.S. Hemodialysis Devices Market: Hemodialysis Machine Installed-Base and Replacement Cycle Analysis
TABLE 28: U.S. Hemodialysis Devices Market: Disposable and Recurring Consumables Revenue Model
TABLE 29: U.S. Hemodialysis Devices Market: Digitalization and Connected Dialysis Care Impact
TABLE 30: U.S. Hemodialysis Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Hemodialysis Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Hemodialysis Devices Market: CMS ESRD Prospective Payment System Analysis
TABLE 33: U.S. Hemodialysis Devices Market: Medicare Home Dialysis Reimbursement Landscape
TABLE 34: U.S. Hemodialysis Devices Market: Medicare and Commercial Payer Coverage Dynamics
TABLE 35: U.S. Hemodialysis Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 36: U.S. Hemodialysis Devices Market: U.S. Kidney Health Programs and Government Initiatives
TABLE 37: U.S. Hemodialysis Devices Market: Environmental Sustainability and Dialysis Water Consumption Analysis
TABLE 38: U.S. Hemodialysis Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 39: U.S. Hemodialysis Devices Market: Dialysis Provider Value Analysis and Procurement Decision Framework
TABLE 40: U.S. Hemodialysis Devices Market: Large Dialysis Organization Enterprise Contracting Analysis
TABLE 41: U.S. Hemodialysis Devices Market: Product Category Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product Category
TABLE 43: U.S. Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 44: U.S. Hemodialysis Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 45: U.S. Hemodialysis Devices Market: Hemodialysis Machines Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Hemodialysis Devices Market: Dialyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Hemodialysis Devices Market: Bloodline Systems, Tubing Sets and Treatment Cartridges Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Hemodialysis Devices Market: Vascular Access Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Hemodialysis Devices Market: Dialysate Concentrates, Water-Treatment Systems and Other Consumables Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Hemodialysis Devices Market: Treatment Modality & Technology Snapshot, 2025
TABLE 51: Segment Dashboard; Definition and Scope, by Treatment Modality & Technology
TABLE 52: U.S. Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 53: U.S. Hemodialysis Devices Market: Segment Share Analysis, by Treatment Modality & Technology, 2025 & 2035 (%)
TABLE 54: U.S. Hemodialysis Devices Market: Conventional In-Center Hemodialysis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Hemodialysis Devices Market: High-Flux Hemodialysis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. Hemodialysis Devices Market: High-Volume Hemodiafiltration Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Hemodialysis Devices Market: Home Hemodialysis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Hemodialysis Devices Market: Acute and Extended Hemodialysis Therapies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Hemodialysis Devices Market: Clinical Application Snapshot, 2025
TABLE 60: Segment Dashboard; Definition and Scope, by Clinical Application
TABLE 61: U.S. Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 62: U.S. Hemodialysis Devices Market: Segment Share Analysis, by Clinical Application, 2025 & 2035 (%)
TABLE 63: U.S. Hemodialysis Devices Market: Chronic End-Stage Kidney Disease Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Hemodialysis Devices Market: Acute Kidney Injury Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. Hemodialysis Devices Market: Cardiorenal and Fluid-Overload Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Hemodialysis Devices Market: Complex and High-Acuity Renal Failure Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Hemodialysis Devices Market: Pediatric Hemodialysis Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Hemodialysis Devices Market: End User Snapshot, 2025
TABLE 69: Segment Dashboard; Definition and Scope, by End User
TABLE 70: U.S. Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 71: U.S. Hemodialysis Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 72: U.S. Hemodialysis Devices Market: Outpatient Dialysis Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Hemodialysis Devices Market: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. Hemodialysis Devices Market: Home Healthcare and Patient Homes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. Hemodialysis Devices Market: Nephrology and Specialty Renal Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Hemodialysis Devices Market: Skilled Nursing and Post-Acute Care Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Hemodialysis Devices Market: Procurement Channel Snapshot, 2025
TABLE 78: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 79: U.S. Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 80: U.S. Hemodialysis Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 81: U.S. Hemodialysis Devices Market: Direct Manufacturer Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. Hemodialysis Devices Market: Large Dialysis Organization and Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Hemodialysis Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. Hemodialysis Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Hemodialysis Devices Market: Home Hemodialysis Program Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Hemodialysis Devices Market: Regional Snapshot, 2025
TABLE 87: Segment Dashboard; Definition and Scope, by Region
TABLE 88: U.S. Hemodialysis Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 89: U.S. Hemodialysis Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 90: West Region U.S. Hemodialysis Devices Market: Regional Overview and Trends
TABLE 91: West Region U.S. Hemodialysis Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 92: West Region U.S. Hemodialysis Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 98: California Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 99: California Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 100: California Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 101: California Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 102: California Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 103: Washington Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 104: Washington Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 105: Washington Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 106: Washington Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: Washington Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 108: Arizona Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 109: Arizona Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 110: Arizona Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 111: Arizona Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 112: Arizona Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 113: Colorado Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 114: Colorado Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 115: Colorado Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 116: Colorado Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: Colorado Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 118: Oregon Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 119: Oregon Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 120: Oregon Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 121: Oregon Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 122: Oregon Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 123: Utah Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 124: Utah Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 125: Utah Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 126: Utah Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: Utah Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 128: Nevada Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 129: Nevada Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 130: Nevada Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 131: Nevada Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: Nevada Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 133: New Mexico Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 134: New Mexico Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 135: New Mexico Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 136: New Mexico Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 137: New Mexico Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 138: Idaho Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 139: Idaho Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 140: Idaho Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 141: Idaho Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 142: Idaho Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 143: Montana Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 144: Montana Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 145: Montana Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 146: Montana Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 147: Montana Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 148: Wyoming Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 149: Wyoming Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 150: Wyoming Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 151: Wyoming Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 152: Wyoming Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 153: Alaska Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 154: Alaska Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 155: Alaska Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 156: Alaska Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Alaska Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 158: Hawaii Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 159: Hawaii Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 160: Hawaii Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 161: Hawaii Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 162: Hawaii Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 163: Northeast Region U.S. Hemodialysis Devices Market: Regional Overview and Trends
TABLE 164: Northeast Region U.S. Hemodialysis Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 165: Northeast Region U.S. Hemodialysis Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 166: Northeast Region U.S. Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 167: Northeast Region U.S. Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 168: Northeast Region U.S. Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 170: Northeast Region U.S. Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 171: New York Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 172: New York Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 173: New York Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 174: New York Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 175: New York Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 176: Massachusetts Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 177: Massachusetts Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 178: Massachusetts Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 179: Massachusetts Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 180: Massachusetts Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 181: New Jersey Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 182: New Jersey Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 183: New Jersey Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 184: New Jersey Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 185: New Jersey Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 186: Pennsylvania Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 187: Pennsylvania Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 188: Pennsylvania Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 189: Pennsylvania Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 190: Pennsylvania Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 191: Connecticut Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 192: Connecticut Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 193: Connecticut Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 194: Connecticut Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 195: Connecticut Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 196: Maine Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 197: Maine Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 198: Maine Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 199: Maine Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 200: Maine Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 201: Vermont Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 202: Vermont Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 203: Vermont Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 204: Vermont Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 205: Vermont Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 206: New Hampshire Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 207: New Hampshire Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 208: New Hampshire Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 209: New Hampshire Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 210: New Hampshire Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 211: Rhode Island Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 212: Rhode Island Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 213: Rhode Island Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 214: Rhode Island Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 215: Rhode Island Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 216: Delaware Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 217: Delaware Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 218: Delaware Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 219: Delaware Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 220: Delaware Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 221: South Region U.S. Hemodialysis Devices Market: Regional Overview and Trends
TABLE 222: South Region U.S. Hemodialysis Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 223: South Region U.S. Hemodialysis Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 224: South Region U.S. Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 225: South Region U.S. Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 226: South Region U.S. Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 228: South Region U.S. Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 229: Texas Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 230: Texas Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 231: Texas Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 232: Texas Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 233: Texas Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 234: Florida Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 235: Florida Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 236: Florida Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 237: Florida Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 238: Florida Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 239: Georgia Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 240: Georgia Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 241: Georgia Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 242: Georgia Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 243: Georgia Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 244: North Carolina Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 245: North Carolina Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 246: North Carolina Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 247: North Carolina Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 248: North Carolina Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 249: Tennessee Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 250: Tennessee Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 251: Tennessee Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 252: Tennessee Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 253: Tennessee Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 254: South Carolina Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 255: South Carolina Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 256: South Carolina Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 257: South Carolina Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 258: South Carolina Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 259: Alabama Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 260: Alabama Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 261: Alabama Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 262: Alabama Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 263: Alabama Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 264: Mississippi Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 265: Mississippi Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 266: Mississippi Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 267: Mississippi Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 268: Mississippi Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 269: Louisiana Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 270: Louisiana Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 271: Louisiana Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 272: Louisiana Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 273: Louisiana Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 274: Arkansas Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 275: Arkansas Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 276: Arkansas Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 277: Arkansas Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 278: Arkansas Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 279: Kentucky Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 280: Kentucky Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 281: Kentucky Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 282: Kentucky Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 283: Kentucky Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 284: Oklahoma Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 285: Oklahoma Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 286: Oklahoma Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 287: Oklahoma Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 288: Oklahoma Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 289: Virginia Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 290: Virginia Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 291: Virginia Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 292: Virginia Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 293: Virginia Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 294: Maryland Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 295: Maryland Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 296: Maryland Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 297: Maryland Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 298: Maryland Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 299: West Virginia Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 300: West Virginia Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 301: West Virginia Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 302: West Virginia Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 303: West Virginia Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 304: Midwest Region U.S. Hemodialysis Devices Market: Regional Overview and Trends
TABLE 305: Midwest Region U.S. Hemodialysis Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 306: Midwest Region U.S. Hemodialysis Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 307: Midwest Region U.S. Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 308: Midwest Region U.S. Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 309: Midwest Region U.S. Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 311: Midwest Region U.S. Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 312: Illinois Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 313: Illinois Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 314: Illinois Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 315: Illinois Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 316: Illinois Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 317: Ohio Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 318: Ohio Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 319: Ohio Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 320: Ohio Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 321: Ohio Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 322: Michigan Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 323: Michigan Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 324: Michigan Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 325: Michigan Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 326: Michigan Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 327: Minnesota Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 328: Minnesota Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 329: Minnesota Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 330: Minnesota Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 331: Minnesota Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 332: Indiana Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 333: Indiana Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 334: Indiana Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 335: Indiana Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 336: Indiana Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 337: Wisconsin Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 338: Wisconsin Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 339: Wisconsin Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 340: Wisconsin Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 341: Wisconsin Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 342: Missouri Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 343: Missouri Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 344: Missouri Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 345: Missouri Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 346: Missouri Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 347: Iowa Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 348: Iowa Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 349: Iowa Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 350: Iowa Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 351: Iowa Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 352: Kansas Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 353: Kansas Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 354: Kansas Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 355: Kansas Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 356: Kansas Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 357: Nebraska Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 358: Nebraska Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 359: Nebraska Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 360: Nebraska Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 361: Nebraska Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 362: North Dakota Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 363: North Dakota Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 364: North Dakota Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 365: North Dakota Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 366: North Dakota Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 367: South Dakota Hemodialysis Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 368: South Dakota Hemodialysis Devices Market, by Treatment Modality & Technology, 2021–2035 (US$ Billion)
TABLE 369: South Dakota Hemodialysis Devices Market, by Clinical Application, 2021–2035 (US$ Billion)
TABLE 370: South Dakota Hemodialysis Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 371: South Dakota Hemodialysis Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 372: U.S. Hemodialysis Devices Market: Competitive Landscape Snapshot, 2025
TABLE 373: U.S. Hemodialysis Devices Market: Key Company Market Share Analysis, 2025
TABLE 374: U.S. Hemodialysis Devices Market: Hemodialysis Machine Market Share Analysis, 2025
TABLE 375: U.S. Hemodialysis Devices Market: Dialyzer Market Share Analysis, 2025
TABLE 376: U.S. Hemodialysis Devices Market: Disposable and Consumables Market Share Analysis, 2025
TABLE 377: U.S. Hemodialysis Devices Market: Vascular Access Product Competitive Positioning
TABLE 378: U.S. Hemodialysis Devices Market: Company Positioning Matrix
TABLE 379: U.S. Hemodialysis Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 380: U.S. Hemodialysis Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 381: Fresenius Medical Care: Company Profile
TABLE 382: Vantive: Company Profile
TABLE 383: B. Braun Medical Inc.: Company Profile
TABLE 384: Nipro Medical Corporation: Company Profile
TABLE 385: Nikkiso Co., Ltd.: Company Profile
TABLE 386: Outset Medical, Inc.: Company Profile
TABLE 387: Quanta Dialysis Technologies: Company Profile
TABLE 388: Diality, Inc.: Company Profile
TABLE 389: Toray Medical Co., Ltd.: Company Profile
TABLE 390: Asahi Kasei Medical Co., Ltd.: Company Profile
TABLE 391: Mozarc Medical: Company Profile
TABLE 392: BD: Company Profile
TABLE 393: Teleflex Incorporated: Company Profile
TABLE 394: Merit Medical Systems, Inc.: Company Profile
TABLE 395: AngioDynamics, Inc.: Company Profile
TABLE 396: Cook Medical: Company Profile
TABLE 397: ICU Medical, Inc.: Company Profile
TABLE 398: Rockwell Medical, Inc.: Company Profile
TABLE 399: Medline Industries, LP: Company Profile
TABLE 400: Cardinal Health, Inc.: Company Profile
TABLE 401: Medical Components, Inc. (Medcomp): Company Profile
TABLE 402: JMS North America Corporation: Company Profile
TABLE 403: Argon Medical Devices, Inc.: Company Profile
TABLE 404: Xylem Inc.: Company Profile
TABLE 405: STERIS plc: Company Profile
TABLE 406: U.S. Hemodialysis Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 407: U.S. Hemodialysis Devices Market: Disruptive Technologies Impact Matrix
TABLE 408: U.S. Hemodialysis Devices Market: High-Volume Hemodiafiltration Opportunity Assessment
TABLE 409: U.S. Hemodialysis Devices Market: Home and Portable Hemodialysis Opportunity Assessment
TABLE 410: U.S. Hemodialysis Devices Market: Automated Hemodialysis Workflow Impact
TABLE 411: U.S. Hemodialysis Devices Market: Advanced Dialyzer Membrane Opportunity Assessment
TABLE 412: U.S. Hemodialysis Devices Market: Connected Dialysis and Predictive Analytics Impact
TABLE 413: U.S. Hemodialysis Devices Market: Water-Efficient Hemodialysis Technology Assessment
TABLE 414: U.S. Hemodialysis Devices Market: Future Machine Replacement Cycle Analysis
TABLE 415: U.S. Hemodialysis Devices Market: Future Dialyzer and Consumables Mix Analysis
TABLE 416: U.S. Hemodialysis Devices Market: Emerging Business Trends
TABLE 417: U.S. Hemodialysis Devices Market: Business Opportunities for Startups and Existing Players
TABLE 418: U.S. Hemodialysis Devices Market: Investment Prioritization Matrix
TABLE 419: U.S. Hemodialysis Devices Market: Technology Commercialization Readiness Matrix
TABLE 420: U.S. Hemodialysis Devices Market: Strategic Recommendations for Hemodialysis Device Manufacturers
TABLE 421: U.S. Hemodialysis Devices Market: Strategic Recommendations for Dialysis Organizations and ESRD Facilities
TABLE 422: U.S. Hemodialysis Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 423: U.S. Hemodialysis Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 424: U.S. Hemodialysis Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 425: U.S. Hemodialysis Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 426: U.S. Hemodialysis Devices Market: Go-to-Market Strategy Considerations
TABLE 427: U.S. Hemodialysis Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 428: U.S. Hemodialysis Devices Market: Pricing and Contracting Strategy
TABLE 429: U.S. Hemodialysis Devices Market: U.S. State Prioritization Strategy
TABLE 430: U.S. Hemodialysis Devices Market: Partnership and Acquisition Opportunity Assessment
TABLE 431: U.S. Hemodialysis Devices Market: Scope Limitation
TABLE 432: U.S. Hemodialysis Devices Market: Data Use Limitation
TABLE 433: U.S. Hemodialysis Devices Market: Market Sizing Limitation
TABLE 434: U.S. Hemodialysis Devices Market: Forecasting Limitation
TABLE 435: U.S. Hemodialysis Devices Market: State-Level Estimate Limitation
TABLE 436: U.S. Hemodialysis Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 437: U.S. Hemodialysis Devices Market: Legal Disclaimer
TABLE 438: U.S. Hemodialysis Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Hemodialysis Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Hemodialysis Clinical Workflow Economics Framework
FIGURE 11: Dialysis Center Capital Procurement Decision Framework
FIGURE 12: U.S. Hemodialysis Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 13: U.S. Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 14: U.S. Hemodialysis Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 15: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 16: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 17: Hemodialysis Machines Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 18: Dialyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: Bloodline Systems, Tubing Sets and Treatment Cartridges Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Vascular Access Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Dialysate Concentrates, Water-Treatment Systems and Other Consumables Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Treatment Modality & Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Treatment Modality & Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Conventional In-Center Hemodialysis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: High-Flux Hemodialysis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: High-Volume Hemodiafiltration Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Home Hemodialysis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Acute and Extended Hemodialysis Therapies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Clinical Application Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Clinical Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Chronic End-Stage Kidney Disease Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Acute Kidney Injury Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Cardiorenal and Fluid-Overload Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Complex and High-Acuity Renal Failure Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Pediatric Hemodialysis Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 37: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Outpatient Dialysis Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Hospitals and Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Home Healthcare and Patient Homes Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Nephrology and Specialty Renal Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Skilled Nursing and Post-Acute Care Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Direct Manufacturer Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Large Dialysis Organization and Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Home Hemodialysis Program Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 51: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: West Region U.S. Hemodialysis Devices Market Share and Leading Players, 2025
FIGURE 53: West Region Market Share Analysis by State, 2025
FIGURE 54: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: California Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 56: Washington Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Arizona Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Colorado Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Oregon Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Utah Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Nevada Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: New Mexico Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Idaho Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Montana Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Wyoming Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Alaska Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Hawaii Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Northeast Region U.S. Hemodialysis Devices Market Share and Leading Players, 2025
FIGURE 69: Northeast Region Market Share Analysis by State, 2025
FIGURE 70: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New York Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Massachusetts Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New Jersey Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Pennsylvania Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Connecticut Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Maine Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Vermont Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Hampshire Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Rhode Island Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Delaware Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: South Region U.S. Hemodialysis Devices Market Share and Leading Players, 2025
FIGURE 82: South Region Market Share Analysis by State, 2025
FIGURE 83: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Texas Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Florida Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Georgia Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: North Carolina Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Tennessee Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: South Carolina Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Alabama Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Mississippi Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Louisiana Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Arkansas Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Kentucky Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Oklahoma Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Virginia Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Maryland Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: West Virginia Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Midwest Region U.S. Hemodialysis Devices Market Share and Leading Players, 2025
FIGURE 100: Midwest Region Market Share Analysis by State, 2025
FIGURE 101: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Illinois Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Ohio Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Michigan Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Minnesota Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Indiana Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Wisconsin Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Missouri Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Iowa Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Kansas Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Nebraska Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: North Dakota Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: South Dakota Hemodialysis Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 115: Company Positioning Matrix
FIGURE 116: Key Player Product Portfolio Benchmarking
FIGURE 117: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 118: Hemodialysis Device Innovation Roadmap
FIGURE 119: High-Volume Hemodiafiltration Adoption Roadmap
FIGURE 120: Home and Portable Hemodialysis Growth Roadmap
FIGURE 121: Connected Dialysis and Predictive Analytics Roadmap
FIGURE 122: Water-Efficient Hemodialysis Technology Opportunity Map
FIGURE 123: Future Market Scenario Analysis, 2026–2035
FIGURE 124: Disruptive Technologies Impact Matrix
FIGURE 125: Emerging Business Trends Matrix
FIGURE 126: Investment Prioritization Matrix
FIGURE 127: Technology Commercialization Readiness Matrix
FIGURE 128: Strategic Growth Roadmap for U.S. Hemodialysis Device Companies
FIGURE 129: Go-to-Market Strategy Framework
FIGURE 130: Product Positioning and Portfolio Expansion Framework
FIGURE 131: Report Scope and Disclaimer Framework